A phase I/II trial of high-dose radioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous stem cell transplant (ASCT) in patients with poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL).

被引：0
|
作者：
Nademanee, A
Molina, A
Forman, SJ
Kogut, N
Yamauchi, D
An, L
White, CA
Raubitschek, A
机构：
[1] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[2] Kaiser Permanente City Hope, Bone Marrow Transplant Program, Duarte, CA 91010 USA
[3] Idec Pharmaceut Corp, San Diego, CA USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
679
引用
收藏
页码：182A / 182A
页数：1
相关论文
共 50 条
  • [41] High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma
    Salar, A
    Martino, R
    Perea, G
    Ribera, JM
    López-Guillermo, A
    Guardia, R
    Escoda, L
    Altés, A
    Sierra, J
    Montserrat, E
    HAEMATOLOGICA, 2002, 87 (10) : 1028 - 1035
  • [42] Safety and efficacy of high-dose cyclophosphamide, etoposide and ranimustine regimen followed by autologous peripheral blood stem cell transplant for patients with diffuse large B-cell lymphoma
    Kobayashi, Yujin
    Hatta, Yoshihiro
    Sugitani, Masahiko
    Hojo, Atsuko
    Nakagawa, Masaru
    Kusuda, Machiko
    Uchino, Yoshihito
    Takahashi, Hiromichi
    Kiso, Satomi
    Hirabayashi, Yukio
    Yagi, Mai
    Kodaira, Hitomi
    Kurita, Daisuke
    Miura, Katsuhiro
    Iriyama, Noriyoshi
    Kobayashi, Sumiko
    Kura, Yoshimasa
    Horikoshi, Akira
    Sawada, Umihiko
    Takeuchi, Jin
    Takei, Masami
    LEUKEMIA & LYMPHOMA, 2014, 55 (11) : 2514 - 2519
  • [43] Feasibility and Efficacy of High-Dose Melphalan, Cyclophosphamide, Etoposide, and Dexamethasone (LEED) Chemotherapy with or without Rituximab Followed by Autologous Stem Cell Transplantation for Aggressive and Relapsed Non-Hodgkin’s Lymphoma
    Li-na Han
    Jin Zhou
    Takayuki Hirose
    Yosuke Imai
    Takuro Ishiguro
    Takaaki Chou
    International Journal of Hematology, 2006, 84 : 174 - 181
  • [44] Feasibility and efficacy of high-dose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin's lymphoma
    Han, Li-na
    Zhou, Jin
    Hirose, Takayuki
    Imai, Yosuke
    Ishiguro, Takuro
    Chou, Takaaki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2006, 84 (02) : 174 - 181
  • [45] Phase 2 Trial of High-Dose Rituximab With High-Dose Cytarabine Mobilization Therapy and High-Dose Thiotepa, Busulfan, and Cyclophosphamide Autologous Stem Cell Transplantation in Patients With Central Nervous System Involvement by Non-Hodgkin Lymphoma
    Chen, Yi-Bin
    Batchelor, Tracy
    Li, Shuli
    Hochberg, Ephraim
    Brezina, Mark
    Jones, Sooae
    Del Rio, Candice
    Curtis, Morgan
    Ballen, Karen K.
    Barnes, Jeffrey
    Chi, Andrew S.
    Dietrich, Jorg
    Driscoll, Jessica
    Gertsner, Elizabeth R.
    Hochberg, Fred
    LaCasce, Ann S.
    McAfee, Steven L.
    Spitzer, Thomas R.
    Nayak, Lakshmi
    Armand, Philippe
    CANCER, 2015, 121 (02) : 226 - 233
  • [46] Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome
    Nieto, Yago
    Popat, Uday
    Anderlini, Paolo
    Valdez, Ben
    Andersson, Borje
    Liu, Ping
    Hosing, Chitra
    Shpall, Elizabeth J.
    Alousi, Amin
    Kebriaei, Partow
    Qazilbash, Muzaffar
    Parmar, Simrit
    Bashir, Qaiser
    Shah, Nina
    Khouri, Issa
    Rondon, Gabriela
    Champlin, Richard
    Jones, Roy B.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (03) : 410 - 417
  • [47] PHASE 2 TRIAL OF HIGH-DOSE GEMCITABINE, BUSULFAN AND MELPHALAN WITH AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR PATIENTS WITH REFRACTORY HODGKIN'S LYMPHOMA (HL)
    Nieto, Y.
    Popat, U.
    Anderlini, P.
    Hosing, C.
    Andersson, B.
    Valdez, B.
    Shpall, E. J.
    Ahmed, S.
    Qazilbash, M.
    Kebriaei, P.
    Alousi, A.
    Bassett, R.
    Oki, Y.
    Fanale, M.
    Hagemeister, F.
    Dabaja, B.
    Reed, V.
    Pinnix, C.
    Tewari, P.
    Worth, L.
    Champlin, R.
    Jones, R. B.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S166 - S166
  • [48] High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma
    Falzetti, Franca
    Di Ianni, Mauro
    Ballanti, Stelvio
    Iodice, Giuseppe
    Reale, Antonia
    Minelli, Olivia
    Serio, Gabriella
    Martelli, Massimo F.
    Dammacco, Franco
    Vacca, Angelo
    Ria, Roberto
    CLINICAL AND EXPERIMENTAL MEDICINE, 2012, 12 (03) : 165 - 171
  • [49] High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma
    Franca Falzetti
    Mauro Di Ianni
    Stelvio Ballanti
    Giuseppe Iodice
    Antonia Reale
    Olivia Minelli
    Gabriella Serio
    Massimo F. Martelli
    Franco Dammacco
    Angelo Vacca
    Roberto Ria
    Clinical and Experimental Medicine, 2012, 12 : 165 - 171
  • [50] A novel high-dose chemotherapy strategy with bendamustine in adjunct to etoposide, aracytin and melphalan followed by autologous stem cell rescue in resistant/relapsed Hodgkin and non-Hodgkin lymphoma patients: a phase I-II study
    Visani, G.
    Malerba, L.
    Stefani, P. M.
    Galieni, P.
    Gherlinzoni, F.
    Giardini, C.
    Falcioni, S.
    Loscocco, F.
    Rocchi, M.
    Isidori, A.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S245 - S245
12345